Thanks for great synopsis on CBST. You're right, the risks are that they are one trick pony and that they lose to Teva earlier than expected. The pipeline looks somewhat weak at a glance, but I am no specialist.
Pharmas are tough for me. I don't understand the pipelines. They had great times decade or two ago, but now it seems the business is hard, lots of investment in R&D and not many blockbuster drugs. You'd think doctors like Ipsofacto and Mike Burry would have much better insight into this, but I haven't seen much of that. There was a guy - Oblomov - who posted here some time ago and had some deeper insights, but even his picks did not do very great from what I remember.
That said, I still hold AMGN, ASRG, DGX, GXDX, MDT, JNJ, GILD, LTUS. Only AMGN and GILD are purebred pharmas though. |
